Source: Annual Congress 2013 –Drug-resistant tuberculosis: new clinical and public health insights
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
D. Falzon, R. D. Menzies, C. L. Daley, C. Lienhardt, A. Khan, M. L. Rich, M. A. Aziz, C. S. B. van Weezenbeek, C. D. Mitnick (Geneva, Switzerland; Montréal, Canada; Denver, Boston, United States Of America; Karachi, Pakistan; Cairo, Egypt; Manila, Philippines). Getting the best possible evidence from observational studies of treatment of multidrug-resistant tuberculosis patients. Eur Respir J 2013; 42: Suppl. 57, 189

Member's Comments

No comment yet.

Related content which might interest you: Effectiveness of mandatory treatment for tuberculosis - An observational registry study Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Guidelines of tuberculosis preventive therapy for HIV-infected persons: a prospective, multicentre study Source: Eur Respir J 2001; 18: 369-375 Year: 2001 Outcomes for multidrug-resistant tuberculosis patients with and without resistance to fluoroquinolones and second-line injectable drugs: A meta-analysis of individual patient data Source: Annual Congress 2012 - Pros and cons of MDR- and XDR-TB treatment Year: 2012 Impact of pre-treatment duration by first line drugs on treatment outcomes of patients with MDR-TB Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Could side effects of MDR-TB treatment change the outcome of the disease? Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Bedaquiline-containing regimens for MDR TB treatment – Focus on the safety Source: International Congress 2016 – Drug-resistant tuberculosis and experiences with delamanid and bedaquiline Year: 2016 Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 Rifampicin-resistant TB on Gene Xpert: What is the best empiric combination treatment while awaiting cultures? Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Interventions to improve retention-in-care and treatment adherence among patients with drug-resistant tuberculosis: a systematic review Source: Eur Respir J, 53 (1) 1801030; 10.1183/13993003.01030-2018 Year: 2019 Multicentre randomised clinic study of new standard chemotherapy regimen for new cases patients of pulmonary tuberculosis executed in Russia regions with high level of multiple drug resistance (MDR) Source: Annual Congress 2009 - Tuberculosis control Year: 2009 WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 Clofazimine for the treatment of multidrug-resistant tuberculosis: Prospective, multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021 Surgical treatment for MDR TB patients – preliminary results from a Romanian MDR TB centre Source: Eur Respir J 2006; 28: Suppl. 50, 276s Year: 2006 Evaluation of optimal regimens for treatment of rifampicin resistant-tuberculosis: Multicenter, randomized controlled study in China Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Recruitment challenges for clinical trials with novel regimens for drug-resistant tuberculosis Source: Eur Respir J 2016; 47: 670-672 Year: 2016 Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis Source: Eur Respir J 2017; 49(1): 1600993; DOI: 10.1183/13993003.00993-2016 Year: 2017 Epidemiology and clinical management of XDR-TB: a systematic review by TBNET Source: Eur Respir J 2009; 33: 871-881 Year: 2009